L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy.

Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan. Electronic address: khayashi@dokkyomed.ac.jp. Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan; Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

Journal of pharmacological sciences. 2022;(1):31-40
Full text from:

Abstract

Ingestion of amino acids is fundamental for cellular activity. Amino acids are important components for protein synthesis but are also crucial for intracellular metabolic reactions and signal transduction. Following activation, immune cells induce metabolic reprogramming to generate adequate energy and constitutive substances. Hence, the delivery of amino acids by transporters is necessary for the progression of metabolic rewiring. In this review, we discuss how amino acids and their transporters regulate immune cell functions, with emphasis on LAT1, a transporter of large neutral amino acids. Furthermore, we explore the possibility of targeting amino acid transporters to improve immune disorders and cancer immune therapies.

Methodological quality

Publication Type : Review

Metadata

MeSH terms : Immunotherapy ; T-Lymphocytes